| Literature DB >> 35662972 |
Juan-Manuel Cortes-Mejia1, Ana Boquete-Castro2, Yoaly Arana-Lechuga1,3, Guadalupe Jovanna Terán-Pérez3, Katiuska Casarez-Cruz4, Rosa Obdulia González-Robles5, Javier Velázquez-Moctezuma1,3.
Abstract
Objectives: This study aimed to evaluate the therapeutic effcacy of custom-made mandibular advancement devices (MAD) in the control of primary snoring and sleep apnea and to correlate with anatomical changes identified through imaging tests.Entities:
Keywords: Mandibular Advance Device; Primary Snoring; Sleep Apnea; sleep disorder
Year: 2022 PMID: 35662972 PMCID: PMC9153980 DOI: 10.5935/1984-0063.20210034
Source DB: PubMed Journal: Sleep Sci ISSN: 1984-0063
Demographic characteristics.
| Variable | Mean (SD) |
|---|---|
| Age (years) | 39.8 (10.7) |
| Gender | 9 ♂ / 8 |
| Body mass index | 24 (1.9) |
| Neck circumference (cm) | 39 (1.7) |
| Diagnosis | OSA (12) / PS (5) |
| Oxygen desaturation index | 27 (34) |
Figure 1Picture of Mandibular Advance Device.
Figure 2Sagittal section to show were the measurements were taken.
Figure 3Timeline.
Sleep variables. Median values of the variables related to sleep continuity and sleep-architecture before and after the use of MADs.
| Variable | Before MAD Median (IQR) | After MAD Median (IQR) | |
|---|---|---|---|
| Sleep latency (min.) | 16 (66) | 12 (47) | 0.02 |
| Total time of sleep (min.) | 424 (154) | 437.5 (146.5) | 0.25 |
| Sleep efficiency (%) | 88 (30.3) | 89 (27.5) | 0.92 |
| WASO (min.) | 26.6 | 30.2 (105) | 0.82 |
| Light sleep (%) | 60.8 (34.6) | 57.0 (28.7) | 0.83 |
| Slow wave sleep (%) | 18.1(31.5) | 20 (34.2) | 0.14 |
| REM sleep (%) | 21.04 (12.3) | 22.5 (14.6) | 0.46 |
| Arousal index | 7.5 (12.3) | 4.1 (17.1) | 0.96 |
p≤0.05.
Figure 4Excessive daytime sleepiness (Epworth Sleepiness Scale), pre (black) post (grey). Paired-Sample T-Test * p = 0.05.
Respiratory parameters.
| n=17 | Before MAD | After MAD | Test | |
|---|---|---|---|---|
| Snore index (IQR) | 174 (557.12) | 8.4 (55) | Wilcoxon signed-rank test | 0.00 |
| AHI (IQR) | 9.9 (57) | 1.3 (21.4) | Wilcoxon signed-rank test | 0.00 |
| Mean SpO2% (SD) | 90.6 (1.17) | 90.8 (1.19) | Paired-sample t- test | 0.075 |
| Min SpO2% (SD) | 81.5 (7.3) | 86.1 (2.4) | Paired-sample t-test | 0.01 |
| ODI (IQR) | 13.6 (94) | 2.9 (93.2) | Wilcoxon signed-rank test | 0.03 |
p<0.05; AHI = Apnea/hypopnea index; ODI: Oxygen desaturation index; IQR = Interquartile range; SD = Standard deviation.
Figure 5Axial and sagittal measurements of the upperway in hard palate, glottic, and supraglottic withouth (white bar) and whit MAD (black bar) MAD. The sagittal dimensions at the level of the hard palate and axial dimensions in the supraglottic area show a significant difference. Shapiro-Wilk. (SHP Sagittal Hard Palate, SS Sagittal Supraglottic, SG Sagittal Glottic AHP Axial Hard Palate, AS Axial Supraglottic, AG Axial Glottic). Paired-Sample T-Test * p = 0.05.
Figure 6Example of the sagittal section and the difference in the pharyngeal dimension at the glottic level with and without the MAD. MAD (mandibular advancement device). Opening of the sagittal section at the glottic level (A: Pharyngeal dimensions without MAD; pharyngeal dimensions with MAD), anteroposterior (A-P) axial section, and the change in the pharyngeal dimension at the hard palate level (B), without and with MAD.